ESTRO37_ProgrammeBook

> Isolated Nodal Failure rates following curative intent radiotherapy in a modern cohort S. McCauley (United Kingdom), K. Tumelty, R. Eakin, J. Harney, L. Young, J. McAleese, G. Hanna > HEmatologic paRaMeters as prEdictive biomarkerS in NSCLC (HERMES-Lung) for metastasis development A. Martino (Italy), J. Lenkowicz, G. Mattiucci, A. Petrone, A. Piras, D. Smaniotto, A. Alitto, C. Mazzarella, G. Palazzoni, M. Congedo, M. Chiappetta, S. Margaritora, V. Valentini, G. Mantini > Outcomes According to SRS Dose Prescription for Brain Metastases from Lung Cancer F. Moraes (Canada), J. Winter, A. Dasgupta, H. Razie, C. Coolens, Z. Gelareh, P. Kongkham, M. Bernstein, T. Conrad, N. Laperriere, B. Millar, A. Berlin, D. Shultz > FDG and FMISO-PET for guided dose escalation with intensity- modulated radiotherapy in lung cancers S. Thureau (France), D. Gensanne, N. Pirault, R. Modzelewski, P. Gouel, P. Bohn, S. Hapdey, P. Vera, B. Dubray > Prognostic value of hematological inflammatory markers in patients with non-small cell lung cancer N. Kishi (Japan), M. Ogura > Clinical outcome and toxicity of stereotactic ablative radiotherapy to centrally located tumors B. Atalar (Turkey), B. Sahin, T. Zoto Mustafayev, G. Gungor, G. Aydin, B. Yapici, E. Ozyar > Non-linear radiomic signatures characterizing overall survival from non-small cell lung cancer M. Field (Australia), L. Holloway, S. Vinod, M.S. Barakat, V. Ahern, M. Bailey, M. Carolan, G. Delaney, A. Ghose, E. Hau, J. Lehmann, T. Lustberg, A.A. Miller, D. Stirling, J. Sykes, J. Van Soest, S. Walsh, A. Dekker, D.I. Thwaites > Assessment of Heart Motion in lung Radiotherapy: making sure your heart’s in the right place D.C.P. Cobben (United Kingdom), M.S. Iqbal, A. Bedair, J. Byrne, H. McCallum

ELECTRONIC POSTERS

EP-1398

EP-1399

EP-1400

EP-1401

EP-1402

EP-1403

EP-1404

EP-1405

POSTERS AND ELECTRONIC POSTERS | Programme and Exhibition Guide

278